All In Biotech

Drug Trial Radar · NCT01623713

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Last checked: Nov 20, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Jun 2012

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Sponsor type
Industry
First posted
Jun 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

Conditions

  • Schizophrenia
  • Iloperidone
  • Efficacy

Interventions

  • iloperidoneDrug

    Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.

  • RisperidoneDrug

    Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive and Negative Symptom Scale(PANSS)-Total ScoreTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sixth Hospital of Peking University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.